Search

Keep up to date with the latest news, innovations, and developments, spotlighting groundbreaking research and emerging players.

Stay informed on the latest financial trends and investment opportunities, from startups to established players.

Explore the intersection of psychedelic medicine and cultural values, diving into ethical considerations and societal impacts within this transformative field.

Navigate the complex legal and political landscape surrounding psychedelic medicine, including regulatory updates, policy changes, and advocacy efforts.

Delve into cutting-edge scientific research and breakthroughs in the field of psychedelic medicine, with a focus on understanding the mechanisms, efficacy, and safety of these substances.

Discover the therapeutic potential of psychedelic substances, examining their role in mental health, personal growth, and overall well-being.

Nov 9-11, 2023 | Miami, FL

The Premier Global Event for Psychedelics, Mental Health & Longevity

Delve into the captivating world of psychedelic medicine at Wonderland, where the frontiers of science, spirituality, and wellness converge to create an experience unlike any other.

Discover the keys to living longer while exploring the potential of humanity’s future. Wonderland brings together the latest groundbreaking research, charting trends, and investment opportunities for an experience of a lifetime.

Uncover state-of-the-art technology, evolving trends, insightful marketing strategies, and valuable opportunities designed for professionals in the mental health and brain care sector.

With this year’s Wonderland, we want to expand the conversation to take a deep dive into the intersection of these fields with psychedelic medicine, and how combining all three can lead to living not only a longer, but happier life.

The premier global conference, Wonderland is a groundbreaking event experience where visionaries and pioneers unite to explore the future of psychedelic medicine, the business of mental health and the future of longevity medicine.

Are you ready to share your passion, knowledge, and insights with a global audience of executives, researchers, and practitioners? This is your opportunity to contribute to the evolving conversation on the future of medicine showcase your unique expertise, and inspire change in the world.

Wonderland presents a one-of-a-kind opportunity for businesses and organizations to exhibit their cutting-edge products, services, and visionary solutions to a captivated audience of professionals in the mental health and psychedelic medicine fields.

We invite companies with a shared vision to submit partnership proposals and collaborate with us on this extraordinary event. By joining forces, we can create a truly unique experience for attendees, foster lasting connections, and drive the future of psychedelic healing together.

Elevate your brand’s presence in the psychedelic medicine industry with our comprehensive suite of services, tailored to captivate your audience, strengthen your market position, and foster meaningful connections within the community.

Our website provides a platform for a range of custom content, putting your message in front of the industry’s most engaged and informed audience.

Our advertising options give you the ability to target users on their desktops, mobile devices, or when they’re at one of our in-person events. You decide when and where to connect with our audience.

Our dedicated team provides passion and specialist insight across a variety of sectors and services so, whatever the challenge, the impact is guaranteed.

You’re doing the hard work of changing the world, let our team of internationally award-winning creators focus on spreading the word as far as possible and telling your story to the world.

Microdose’s events and conferences are bringing psychedelic medicine to the mainstream. Top investors, business leaders, researchers, and advocates — our events are the hub for the psychedelic renaissance.

Justin Hanka
MindBio Therapeutics

The team at Microdose are leaders in public relations activities and have successfully assisted MindBio Therapeutics to reach a global audience that we would not have been able to reach without them.

Natalie Dolphin
Wellbeing Digital Science

The Microdose team worked with us, identifying key activities we were undertaking and promoting them through its wide-ranging media connections within psychedelics, cannabis and biotech publications. The Microdose team is professional and passionate about what it does, and this was reinforced during the pandemic when it went above and beyond our agreed contract, working with us to get key messages out to the industry quickly and effectively.

Microdose X is shifting the world’s perception of psychedelic medicine, one city at a time. Join the world’s fastest-growing psychedelic network and enjoy vibrant local meetups with like-minded souls.

The Science of Psychedelics is an accredited, definitive guide to the clinical applications of entheogenic medicines, and offers a solid introduction to psychedelic-assisted therapy and “trip sitting” skills to physicians, psychologists, social workers, mental health counselors, pharmacists, and other empowered individuals. Become trained in psychedelic medicines like psilocybin, LSD, MDMA, and ketamine today.

Psychedelia is a quarterly publication examining the ever-changing realm of drug policy and efforts to bring psychedelic therapies into the mainstream. From psilocybin mushrooms to LSD to DMT, psychedelics have the potential to revolutionize mental healthcare in North America. Psychedelia will detail the journey towards acceptance of psychedelic-assisted therapies.

Microdose is a small team of people who want to help share the potential of psychedelic medicine with the world, bringing together our unique expertise and diverse backgrounds to create a platform that inspires, informs, and fosters a thriving community in this transformative field.

Our team shares a passion for psychedelic medicine and we all have a different story on how we ended up here. We want to share those stories and highlight the amazing people that help us do what we do.

Connect with our team to explore how we can collaborate and unlock the potential of psychedelic medicine together, fostering growth and innovation in this dynamic industry.

PsyBio Therapeutics Announces Retention of Market Maker

TORONTO, March 04, 2021 (GLOBE NEWSWIRE) — PsyBio Therapeutics Corp. (TSXV:PSYB) (“PsyBio” or the “Company”), a leader in the field of psychedelic research and drug development, announces that, subject to the receipt of approval by the TSX Venture Exchange (“TSXV”), it has retained Generation IACP Inc. (“Generation”) to provide market making services with the objective of maintaining a reasonable market and improving the liquidity of PsyBio shares traded on the TSXV. PsyBio and Generation are unrelated and unaffiliated entities. Generation is a member of the Investment Industry Regulation Organization of Canada (IIROC) and a member firm of the TSXV.

Under the agreement between Generation and the Company (the “Generation Agreement”), the Company has agreed to initially pay Generation a fee of CAD$7,500 plus applicable taxes per month for a six-month term, subject to termination in accordance with the notice provisions provded for in the Generation Agreement. Generation will not receive any securities as compensation. Generation does not currently own any securities of PsyBio; however, Generation and its clients may acquire a direct interest in the securities of the Company.

About PsyBio Therapeutics Corp.

PsyBio is a biotechnology company developing novel formulations of psychoactive medications using genetically modified bacteria for the treatment of mental health and other disorders. The team has experience in drug discovery based on synthetic biology and clinical and regulatory experience moving drugs through human studies and regulatory protocols. Research and development are currently ongoing for natural occurring tryptamines in different varieties of magic mushrooms, dimethyltryptamine and its derivatives, and mescaline and combinations thereof. The Company is also researching and developing new molecular structures that do not occur in nature which may have unique therapeutics properties.

Continue on your trip...

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: the retention of Generation will help maintain a reasonable market and improve the liquidity of PsyBio Shares traded on the TSXV; PsyBio will be successful in protecting its intellectual property within the next year and filing new patent applications within that timeframe; the Company’s success in discovering new valuable target molecules; and the safety and efficacy of PsyBio’s technology and that such technology will be cheaper, faster and greener than other published methods. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting PsyBio’s business and results of operations; decreases in the prevailing process for psilocybin and nutraceutical products in the markets in which PsyBio operates; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

PsyBio makes no medical, treatment or health benefit claims about PsyBio’s proposed products. The U.S. Food and Drug Administration (the “FDA”) or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products have not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio’s performance and operations.

The TSX Venture Exchange (the “TSXV”) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

For further information contact: 

Evan Levine 
CEO, PsyBio Therapeutics Corp. 
t: 226.286.0348
e: ir@psybiolife.com

Media Enquiries:

Kirsten Frazer, PhD
LifeSci Communications
t: 646.863.0222
e: kfrazer@lifescicomms.com

Learn more about the psychedelics industry at Microdose.

Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Follow us on social